Lipocine Inc. Files 8-K

Ticker: LPCN · Form: 8-K · Filed: 2025-09-26T00:00:00.000Z

Sentiment: neutral

Topics: 8-k, filing, sec

TL;DR

Lipocine filed an 8-K on 9/26/25. Standard update.

AI Summary

Lipocine Inc. filed an 8-K on September 26, 2025, reporting on other events and financial statements. The filing does not detail specific transactions or financial figures but serves as a notification of these items.

Why It Matters

This filing indicates Lipocine Inc. is providing updates on its corporate activities and financial status to the SEC, which is standard procedure for public companies.

Risk Assessment

Risk Level: low — This is a routine filing with no immediate disclosed material events or financial changes.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Lipocine Inc.?

The primary purpose is to report on 'Other Events' and 'Financial Statements and Exhibits' as of September 26, 2025.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is September 26, 2025.

What is Lipocine Inc.'s principal executive office address?

Lipocine Inc.'s principal executive office is located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.

What is the Commission File Number for Lipocine Inc.?

The Commission File Number for Lipocine Inc. is 001-36357.

Does this filing indicate any specific new material events or transactions?

The filing indicates 'Other Events' and 'Financial Statements and Exhibits' but does not specify the details of any new material events or transactions within the provided text.

From the Filing

0001493152-25-015081.txt : 20250926 0001493152-25-015081.hdr.sgml : 20250926 20250926093148 ACCESSION NUMBER: 0001493152-25-015081 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20250926 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250926 DATE AS OF CHANGE: 20250926 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 251345706 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 8-K 1 form8-k.htm 8-K false 0001535955 0001535955 2025-09-26 2025-09-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): September 26, 2025     LIPOCINE INC. (Exact name of registrant as specified in its charter)   Commission File No. 001-36357   Delaware   99-0370688 (State or other jurisdiction of incorporation)   (IRS Employer Identification Number)   675 Arapeen Drive , Suite 202 Salt Lake City , Utah 84108 (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code: (801) 994-7383   Former name or former address, if changed since last report: Not Applicable       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   LPCN   The NASDAQ Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 8.01 Other Events   The Company has updated its corporate presentation that it uses when meeting with investors, analysts and others. Although the Company has received IND clearance to proceed with the POC study of LPCN 2401 as an adjunct to GLP-1 therapy, the Company is seeking regulatory clarity regarding the development path for LPCN 2401, in particular study endpoints such as functional loss, before proceeding with the POC study. The corporate presentation has been updated accordingly. The presentation is filed as Exhibi

View on Read The Filing